Search results
Author(s):
Sergio Fazio
Added:
3 years ago
Current Indications for Statin and Fibrate Therapy
The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered:
statins equally reduce risk in subjects with or without…
View more
Author(s):
Frederick Raal
Added:
7 months ago
ESC 23 — Prof Frederick Raal (University of the Witwatersrand, Johannesburg, SA) outlines the late-breaking results from the LIBerte-HeFH study (NCT04797104).
The phase III LIBerte-HeFH study (LIB Therapeutics LLC) aimed to assess the effectiveness of PCSK9-inhibitor Ierodalcibep (LIB003) in reducing low-density lipoprotein cholesterol (LDL-C) in 300mg doses administered subcutaneously in…
View more
Treating the Common Dyslipidemia in Patients with Type 2 Diabetes—The Effects of Fenofibrate on…
Author(s):
Sergio Fazio
Added:
3 years ago
Article
Author(s):
Mohit Gupta
,
Borut Jug
,
Matthew J Budoff
Added:
3 years ago
Diabetes and Cardiovascular Disease
Diabetes has long been recognized as a major risk factor for cardiovascular disease and is widely regarded as a ‘coronary disease equivalent,’1,2 as diabetes and established coronary heart disease indicate a similar absolute risk for cardiovascular death in both men and women.3–5 Cardiovascular complications of diabetes have traditionally been regarded as…
View more
Author(s):
Peter H Jones
Added:
3 years ago
High Residual Cardiovascular Risk in Diabetic Patients Treated with Statins
According to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII), diabetes is a coronary heart disease (CHD) risk equivalent.1 One major factor contributing to the excess risk of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) is atherogenic dyslipidemia,…
View more
Author(s):
Heather Currie
,
Christine Williams
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of death in both men and women, yet the extent of the problem in women is frequently underestimated and, compared with men, women are less likely to be offered interventions, are less likely to be represented in clinical trials and have a worse prognosis. This article aims to examine the extent of the problem of CVD in women, summarise the…
View more
Author(s):
Jiaqian Xu
,
Michael D Shapiro
Added:
3 years ago
Author(s):
Nieca Goldberg
Added:
3 years ago
Cardiovascular disease (CVD) is the leading cause of death and disability in American women. Since 1984, more women have died of cardiovascular disease than men. More than 200,000 of these deaths are due to coronary heart disease.1 In two-thirds of these women, sudden death was the presenting symptom and studies2 show that 90% of them had at least one of the modifiable risk factors (e.g…
View more
Author(s):
Evan A Stein
Added:
3 years ago
Proprotein convertase subtilisin/kexin type 9 (PCSK9), discovered in 2003, is a circulating protein produced predominantly in the liver that plays a significant role in the recycling of LDL receptors (LDLRs).1,2 The LDLR, which normally recycles about 100 times in its lifetime, is the primary pathway for LDL-cholesterol (LDL-C) clearance from circulation. Plasma PCSK9 binds to LDLRs along with…
View more
Author(s):
Christie Ballantyne
Added:
1 year ago
ACC.23/WCC—We are joined by Dr Christie Ballantyne (Baylor College of Medicine, US) to discuss the results of a phase 2b clinical trial on the efficacy and safety of MK-0616, an oral macrocyclic PCSK9 inhibitor.In this trial sponsored by Merck Sharp & Dohme LLC, MK-0616 was compared to a placebo in over 380 participants with hypercholesterolemia, whose low-density lipoprotein cholesterol (LDL-C)…
View more